Royalty Pharma plc
Royalty Pharma plc (RPRX) Revenue
Annual & quarterly revenue history · segment & region breakdown
RPRX · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsRoyalty Pharma plc trailing twelve-month (TTM) revenue is $2.44B, an increase of 5.06% year-over-year from $2.38B in FY2025.
Revenue trend
2025 – 2015 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $2.38B | +$0.11B | +5.06% |
| 2024-12-31 | $2.26B | -$0.09B | -3.86% |
| 2023-12-31 | $2.35B | +$0.12B | +5.24% |
| 2022-12-31 | $2.24B | -$0.05B | -2.28% |
| 2021-12-31 | $2.29B | +$0.17B | +7.87% |
| 2020-12-31 | $2.12B | +$0.31B | +16.98% |
| 2019-12-31 | $1.81B | +$0.02B | +1.08% |
| 2018-12-31 | $1.79B | +$0.20B | +12.33% |
| 2017-12-31 | $1.60B | -$0.28B | -14.89% |
| 2016-12-31 | $1.88B | +$0.22B | +13.62% |
Compare revenue vs peers
BiotechnologyCompare RPRX revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Royalty Pharma plc receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Royalty Pharma plc reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Royalty Pharma plc's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
RPRX revenue · 4 questionsRPRX's trailing twelve-month (TTM) revenue is $2.44B. That is an increase of 5.06% year-over-year from $2.38B in FY2025.
▸ Source: FMP · Royalty Pharma plc SEC filings · GAAP · Royalty Pharma plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026